- Home
- NCA vs ITOS Comparison
NCA vs ITOS Comparison
Compare NCA & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- ITOS
- Stock Information
- Founded
- NCA 1987
- ITOS 2011
- Country
- NCA United States
- ITOS United States
- Employees
- NCA N/A
- ITOS N/A
- Industry
- NCA Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCA Finance
- ITOS Health Care
- Exchange
- NCA Nasdaq
- ITOS Nasdaq
- Market Cap
- NCA 284.4M
- ITOS 270.7M
- IPO Year
- NCA N/A
- ITOS 2020
- Fundamental
- Price
- NCA $8.71
- ITOS $6.76
- Analyst Decision
- NCA
- ITOS Strong Buy
- Analyst Count
- NCA 0
- ITOS 3
- Target Price
- NCA N/A
- ITOS $26.00
- AVG Volume (30 Days)
- NCA 59.6K
- ITOS 384.6K
- Earning Date
- NCA 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- NCA 3.92%
- ITOS N/A
- EPS Growth
- NCA N/A
- ITOS N/A
- EPS
- NCA N/A
- ITOS N/A
- Revenue
- NCA N/A
- ITOS $35,000,000.00
- Revenue This Year
- NCA N/A
- ITOS N/A
- Revenue Next Year
- NCA N/A
- ITOS $121.70
- P/E Ratio
- NCA N/A
- ITOS N/A
- Revenue Growth
- NCA N/A
- ITOS 177.89
- 52 Week Low
- NCA $7.77
- ITOS $6.67
- 52 Week High
- NCA $9.12
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- NCA 46.35
- ITOS 42.10
- Support Level
- NCA $8.52
- ITOS $6.73
- Resistance Level
- NCA $8.68
- ITOS $7.65
- Average True Range (ATR)
- NCA 0.07
- ITOS 0.38
- MACD
- NCA -0.01
- ITOS -0.00
- Stochastic Oscillator
- NCA 31.82
- ITOS 21.94
About NCA Nuveen California Municipal Value Fund
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.